Compare HubSpot Inc (HUBS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Natera Inc. Common Stock — how do they compare? HubSpot Inc trades at $226.2 (market cap $11.03B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 5.2× HubSpot Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and Natera Inc. Common Stock for 0 Days on average.
| HUBS | NTRA | |
|---|---|---|
Market Cap | $11.03B | $57.03B |
Volume | 784,639 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $494.58 | $425.64 |
52-Week Low | $170.39 | $179.42 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $9.93B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $226.23, up 1.28% today, with a neutral technical signal and strong fundamental growth. The stock has beaten earnings estimates for the last three quarters, with revenue growing from $1.7B in 2022 to $3.1B in 2025. Recent news highlights an AI-focused strategy and partnership with OpenAI, aiming to boost margins and customer outcomes.
The outlook is positive with 55% analyst buy ratings and a $244.09 consensus price target, suggesting 8% upside. Key risks include high valuation multiples and competitive pressures in the SaaS space. Cash flow growth and institutional accumulation support the bullish case, but investors should monitor execution of AI initiatives and margin targets.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
